Odonate Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 27.763 million compared to USD 24.627 million a year ago. Net loss was USD 26.627 million compared to USD 23.926 million a year ago. Basic loss per share was USD 0.88 compared to USD 0.98 a year ago. For the nine months, operating loss was USD 86.221 million compared to USD 61.287 million a year ago. Net loss was USD 83.974 million compared to USD 60.197 million a year ago. Basic loss per share was USD 3.15 compared to USD 2.47 a year ago.